Preface content

A neutralising antibody selected from plasma cells that binds to group 1 and group 2 influenza A haemagglutinins

The isolation of broadly neutralizing antibodies against influenza A viruses has been a long-sought goal for therapeutic approaches and vaccine design. Using a single-cell culture method for screening large numbers of human plasma cells, we isolated a neutralizing monoclonal antibody that recognized the hemagglutinin (HA) glycoprotein of all 16 subtypes and neutralized both group 1 and group 2 influenza A viruses. Passive transfer of this antibody conferred protection to mice and ferrets. Complexes with HAs from the group 1 H1 and the group 2 H3 subtypes analyzed by x-ray crystallography showed that the antibody bound to a conserved epitope in the F subdomain. This antibody may be used for passive protection and to inform vaccine design because of its broad specificity and neutralization potency.

http://www.ncbi.nlm.nih.gov/pubmed/21798894

 

Call to action content

Newsletter

Trim content

Copyright: The Pirbright Institute 2014-2020 | A company limited by guarantee, registered in England no. 559784. The Institute is also a registered charity.

 

Site by Lightflows